CN Patent

CN106890148A — 一种达比加群酯片剂及其制备

Assigned to Qingdao Huanghai Pharmaceutical Co Ltd · Expires 2017-06-27 · 9y expired

What this patent protects

本发明属于医药技术领域，具体的说是一种改良的含达比加群酯或其盐或水合物的片剂及其制备方法。片剂由活性成分、片剂辅料、包衣的酸性颗粒和片剂包衣组成；按重量份数计，活性成分：片剂常用辅料：包衣的酸性颗粒：片剂包衣＝(1-20)：(1-50)(1-40)：(1-15)；其中，活性成分为达比加群酯、达比加群酯盐或达比加群酯水合物。本发明所述制备达比加群酯片剂的工艺简单，片剂溶出更稳定，片剂之间释放差异小。

USPTO Abstract

本发明属于医药技术领域，具体的说是一种改良的含达比加群酯或其盐或水合物的片剂及其制备方法。片剂由活性成分、片剂辅料、包衣的酸性颗粒和片剂包衣组成；按重量份数计，活性成分：片剂常用辅料：包衣的酸性颗粒：片剂包衣＝(1-20)：(1-50)(1-40)：(1-15)；其中，活性成分为达比加群酯、达比加群酯盐或达比加群酯水合物。本发明所述制备达比加群酯片剂的工艺简单，片剂溶出更稳定，片剂之间释放差异小。

Drugs covered by this patent

Patent Metadata

Patent number
CN106890148A
Jurisdiction
CN
Classification
—
Expires
2017-06-27
Drug substance claim
No
Drug product claim
No
Assignee
Qingdao Huanghai Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.